Coronavirus Update: Moderna Prepares For Crucial Phase II Trial Of Vaccine, Japan Takes Steps
At Risk Age Groups Added To Phase I Studies
Plus: Japan pledges rapid approval for remdesivir, GSK launches fund to look into impact of coronavirus on people with HIV.
You may also be interested in...
The US behemoth and its German partner have said that if their mRNA vaccine proves to be safe and effective, it could be ready for US distribution by the end of the year.
US cost watchdog ICER has released its cost models for remdesivir, and says it wants to stimulate debate on how it and other COVID-19 therapies should be priced. Plus news from Amgen and ILC Therapeutics.
In a preliminary assessment of repurposed COVID-19 treatments by a government-appointed panel to assess the readiness and potential of a drug to be used in India, favipiravir and tocilizumab have emerged as front-runners. With Strides Pharma exporting the antiviral and Glenmark set to begin clinical trials, even the industry is supporting favipiravir, which is already in studies in Japan and China.